Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 3/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7364885 | 1.00 | FADS1 (0.50) | FADS1DDB1CRBNALOX5BRD4 | |
| SCHEMBL7364886 | 1.00 | FADS1 (0.50) | FADS1DDB1CRBNALOX5BRD4 | |
| SCHEMBL15743971 | 0.82 | ALOX5 (0.41) | FADS1DDB1CRBNALOX5 | |
| SCHEMBL26548286 | 0.82 | FADS1 (0.44) | FADS1DDB1CRBNALOX5CYP19A1 | |
| SCHEMBL23846740 | 0.82 | FADS1 (0.59) | FADS1ALOX5MAOB | |
| SCHEMBL15743999 | 0.82 | ALOX5 (0.49) | FADS1ALOX5HSD11B1MAOBCYP19A1 | |
| SCHEMBL10725882 | 0.80 | ALOX5 (0.51) | ALOX5CYP19A1 | |
| SCHEMBL15928300 | 0.80 | HTR6 (0.52) | FADS1ALOX5HTR6TSHR | |
| SCHEMBL15928323 | 0.80 | KDM4E (0.48) | ALOX5KDM4ETSHR | |
| SCHEMBL15744000 | 0.78 | FADS1 (0.41) | FADS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2020206424-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2019060742-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC (US) | 2019-03-28 | — | — | WO | disclosed |
| EP-3239137-B1 | (5R)-4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AS WELL AS 1-(2-CHLOROACETYL)-4-PIPERIDINE-CARBONITRILE AND -CARBOXAMIDE DERIVATIVES AS INTERMEDIATES IN THE PREPARATION OF E.G. 4-[4-[(5R)-4,5-DIHYDRO-ISOXAZOL-3-YL]-THIAZOL-2-YL]-PIPERIDINE DERIVATIVES AS FUNGICIDES FOR CROP PROTECTION | DU PONT (US) | 2019-02-13 | — | — | EP | disclosed |
| US-9920030-B2 | Fungicidal azocyclic amides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920030-B2 | Fungicidal azocyclic amides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3239145-A1 | 1-[2-[3,5-SUBSTITUTED-1H-PYRAZOL-1-YL]ACETYL]-4-PIPERIDINE-CARBONITRILE AND -CARBOTHIAMIDE DERIVATIVES AS INTERMEDIATES IN THE PREPARATION OF FUNGICIDES FOR CROP PROTECTION | E. I. du Pont de Nemours and Company (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2712616-B1 | Intermediates for the preparation of 1-(acetyl)-piperidine and 1-(acetyl)-piperazine derivatives as fungicides for use in plant protection | DU PONT (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9604962-B2 | Fungicidal azocyclic amides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| WO-2008013622-A2 | FUNGICIDAL AZOCYCLIC AMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-01-31 | — | — | WO | disclosed |
| US-RE38947-E1 | Method of enantioselectively catalyzing a reaction | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2006-01-24 | — | — | US | disclosed |
| EP-1399420-A2 | PYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002530-A2 | PYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-0594608-B1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS | RES CORP TECHNOLOGIES INC (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0594608-A1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. | RES CORP TECHNOLOGIES INC (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5296595-A | Metal complexes with bridging ligands | RESEARCH CORPORATION TECHNOLOGIES (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0594608-A4 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. | RES CORP TECHNOLOGIES INC (US) | 1993-03-15 | — | — | EP | disclosed |
| US-5175311-A | Reacting olefin with carbene precursor | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-12-29 | — | — | US | disclosed |
| WO-1991014672-A1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | FADS1 3404/4885DDB1 660/4885CRBN 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.